Skip to content

Assessing Brain Changes Throughout the ABI Wellness Program

Assessing Neurophysiological Changes in Individuals With Chronic Traumatic Brain Injury Symptoms Throughout a Full-time or Part-time Holistic Cognitive Rehabilitation Program: An Initial Assessment.

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03438851
Enrollment
7
Registered
2018-02-20
Start date
2018-03-07
Completion date
2020-04-21
Last updated
2021-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Brain Injuries

Brief summary

Symptoms resulting from mild/moderate trauma to the brain are as varied as the individuals who sustain them. The currently held belief is that the majority of healing and functional recovery occurs within the first two years post injury. A large proportion of individuals who sustain mild/moderate brain injuries (mTBIs) do not fully recover, and continue to experience symptoms well beyond two years post injury. Cognitive rehabilitation programs have been shown to be somewhat effective in helping mTBI patients regain some functionality in these executive domains. The purpose of the current study is to use an objective assessment of brain function to track changes during either a full-time or part-time holistic cognitive rehabilitation program, specifically the ABI Wellness (ABIW) program. The NeuroCatch Platform™ test will be used to assess brain functioning before, during and after 3 months in the ABIW program. The NeuroCatch Platform™ test uses electroencephalography (EEG) to measure event-related potential (ERP) signals produced by the brain, in response to an auditory stimulus. Three brain processes are examined with this test: Auditory sensation (ERP marker is the N100), Basic attention (ERP marker is the P300), and Cognitive processing (ERP marker is the N400).

Interventions

NeuroCatch Platform™ consists of software and hardware that captures brain health information. The platform intends to provide a quick, portable and easy to use solution for the acquisition, display, analysis, storage, reporting and management of electroencephalograph (EEG) and event-related potential (ERP) information.

Sponsors

NeuroCatch Inc.
Lead SponsorINDUSTRY

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE

Intervention model description

Participants will self-select into one of two treatment conditions: a full-time intensive program or a part-time program. Participants in the full-time program will be asked to complete 4 experimental sessions with the NeuroCatch PlatformTM over the course of 3 months (i.e. one session/ month); whereas, participants in the part-time program will be asked to complete 3 scans over 3 months (i.e. one session/1.5 months).

Eligibility

Sex/Gender
ALL
Age
19 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

1. Enrolled in but not initiated the ABI Wellness program 2. Male or female, 19-65 years old inclusively 3. Normal hearing capabilities 4. Able to understand the informed consent form, study procedures and willing to participate in study 5. Able to keep eyes still for 6 minutes

Exclusion criteria

1. Clinically documented hearing issues (e.g. in-ear hearing problems, punctured ear drum, etc.) 2. Score of 7 or lower on the Mini Mental State Exam (MMSE) - Orientation subscale 3. Implanted pacemaker 4. Metal or plastic implants in skull 5. In-ear hearing aid or cochlear implant, hearing device 6. Recent (within last 6 months) acquired brain injury 7. History of other neurological disorder (e.g. brain cancer, dementia, multiple sclerosis, stroke, etc.) 8. Exposed to investigational drug or device 30 days prior to start in this study, or concurrent use of investigational drug or device while enrolled in this study 9. Not fluent in English language 10. Unable to provide informed consent 11. Previous participation in studies using the NeuroCatch Platform™ 12. If female and of child-bearing potential: pregnant, suspected or planning to become pregnant or breast-feeding 13. History of seizures 14. Allergy to rubbing alcohol or EEG gel

Design outcomes

Primary

MeasureTime frameDescription
Tracking and comparison of neurophysiological changes (response size) to functional changes as participants complete 3 months of the ABIW program.3 monthsResponse size will be measured as amplitude in microvolts. Functional changes will be measured using a proprietary BrainEx Assessment that provides a category score from four cognitive programs of BrainEx.
Tracking and comparison of neurophysiological changes (response timing) to functional changes as participants complete 3 months of the ABIW program.3 monthsResponse timing will be measured as latency in milliseconds. Functional changes will be measured using a proprietary BrainEx Assessment that provides a category score from four cognitive programs of BrainEx.

Secondary

MeasureTime frameDescription
Collection and evaluation of adverse events and adverse device effects3 monthsEvaluate the tolerability and performance of the NeuroCatch Platform™ with individuals who have chronic cognitive deficits due to traumatic brain injury.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026